Participated · Seed · Oct 2022

Axoft develops implantable brain-computer interfaces (iBCIs) built from its proprietary bio-inspired Fleuron™ material, designed to improve biocompatibility and neural data quality. Fleuron is reported to be up to 10,000x softer than polyimide, offers greater region access and higher sensor/stimulator density per thread, and reduces signal attenuation versus standard flexible probes. The company has demonstrated first-in-human implants in more than 11 patients and completed a study at The Panama Clinic with four patients undergoing tumor resection, recording cortical and subcortical activity. Axoft has research published in Nature (December 2023 and June 2025) showing scalable single-cell electrophysiology enabled by its materials and interfaces. The company has commercialized Fleuron via an exclusive licensing agreement with Stanford and secured a joint development agreement with Kayaku Advanced Materials, alongside grant funding to build a GMP manufacturing facility. Co-founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft has opened a subsidiary in Grenoble, France, and plans to scale manufacturing and expand engineering, microfabrication and chemistry teams as it advances clinical programs and regulatory work.

Participated · Series A · Aug 2022

Fomo Pay provides a one-stop shop for retailers in Singapore and Malaysia, supporting payment options such as WeChat Pay, Baidu Wallet, GrabPay and Visa QR. Founded in 2015, the company offers aggregated payment acceptance and merchant services. In September 2021 it obtained Monetary Authority of Singapore licenses to run merchant acquisition, a domestic money transfer service, and a digital payment token service. Management says transaction volume in the first half of the year exceeded total transactions for all of 2021 and that it has a "very robust" client pipeline. With the new funding the company plans to hire more staff, improve infrastructure, expand its product line, and collaborate with authorities on central bank digital currency initiatives.

Participated · Series C · Nov 2021

Shanghai Zhenyun Technology is a China-based supply chain software provider and operator of the Going-Link cloud software platform. The company offers digital procurement services via its Going-Link platform. Zhenyun closed a RMB650 million (US$102 million) Series C financing. The round was led by Meituan's corporate venturing unit Dragonball Capital and included C&D Emerging Investment (an affiliate of Xiamen C&D) along with several other institutional backers. The article does not disclose operating metrics, revenue, user counts, or specific future plans.

Participated · Series F · Aug 2021

Yuanxin Technology builds a digital healthcare platform that connects doctors, hospitals, pharmaceutical companies, insurers and patients via services including Miaoshou Doctor, Yuanxin Pharmacy and Yuanxin Huibao. It provides in-hospital and out-of-hospital integrated diagnosis and treatment solutions, one-stop pharmacy and hospitalization payment, digital-driven marketing and patient rehabilitation support for pharmaceutical companies, and full-stack insurance operation solutions. After this financing, the company plans to expand its service network for discharged patients, customize post-visit disease course management for multi-disease patients, and accelerate construction of a digitized hospital network and a full-cycle patient portal. Yuanxin also intends to further develop multi-disease and multi-form health insurance products and build digital infrastructure—IT and data systems—that connect patients, doctors, hospitals, pharmaceutical companies, and insurers. Founded in 2015, the company says it has taken a leading role in the “hospital-medication-insurance-patient” model and has maintained sustained rapid growth and top industry positioning. The company completed over ¥1.5 billion in Series F financing, which will support its expansion and digitalization plans. Beijing Yuanxin Technology Co., Ltd is a specialist in digital healthcare and chain pharmacies, operating both digital health services and pharmacy chains. The company focuses on integrating digital healthcare solutions with traditional pharmacy operations. It is identified by its Beijing affiliation in the company name. Recently it completed a major financing round, indicating investor confidence in its business model. No operating metrics or revenue figures were disclosed in the article. Future plans were not specified in the article. Beijing Yuanxin Technology Company Limited, also known as Miaoshou Doctor, is described in reporting as a digital/internet health service provider. The company operates in online health services under the Miaoshou Doctor name. According to the coverage, it has secured an aggregate of 600 million yuan, roughly $85 million. That amount was raised in a Series D1 round. Investors named in the reporting include Sequoia and Qiming, alongside other unspecified participants. The article does not disclose additional operating metrics, valuation, or founding-year information. Miaoshou Doctor is a China-based company reported in DealStreetAsia's roundup of Chinese funding news. The article states the company completed a 500 million-yuan Series C+ financing (about $72.77 million). The report identifies Starquest Capital as the lead investor for the round. The article does not provide details on Miaoshou Doctor’s core product, operating metrics, or future plans. This funding announcement was reported alongside other China tech deals, including SenseTime’s investment in WeRide.